PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
Both companies reducing costs. Martin Whitman would check industry efficiency trends.
41.00%
Gross profit growth below 50% of GNPX's 629.75%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-31.86%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-15.50%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.75%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-27.36%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
Both companies reducing D&A. Martin Whitman would check industry patterns.
28.32%
EBITDA growth 1.25-1.5x GNPX's 23.12%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
27.93%
Operating income growth 1.25-1.5x GNPX's 23.11%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
-5.21%
Other expenses reduction while GNPX shows 50.95% growth. Joel Greenblatt would examine advantage.
29.77%
Pre-tax income growth 1.25-1.5x GNPX's 23.48%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
128.31%
Tax expense growth 1.25-1.5x GNPX's 100.01%. Martin Whitman would scrutinize strategy.
29.77%
Net income growth 1.25-1.5x GNPX's 23.48%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
30.61%
EPS growth 1.25-1.5x GNPX's 25.56%. Bruce Berkowitz would examine sustainability.
30.61%
Diluted EPS growth 1.25-1.5x GNPX's 25.56%. Bruce Berkowitz would examine sustainability.
2.13%
Share count reduction below 50% of GNPX's 2.91%. Michael Burry would check for concerns.
2.13%
Diluted share reduction below 50% of GNPX's 2.92%. Michael Burry would check for concerns.